NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer prot...
Q1 2026
May 7, 2026
FY 2025
Feb 18, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 6, 2025